Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study [Sarcomas]

Conclusion
Trabectedin plus doxorubicin did not show superiority over doxorubicin alone as first-line treatment of advanced STS. The prognostic role of apoptotic key genes, FAS and p53, was shown to be robust enough to continue this research line.

Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Martin-Broto, Pousa, de las Penas, Garcia del Muro, Gutierrez, Martinez-Trufero, Cruz, Alvarez, Cubedo, Redondo, Maurel, Carrasco, Lopez-Martin, Sala, Meana, Ramos, Martinez-Serra, Lopez-Guerrero, Sevilla, Balana, Vaz, De Juan, Alemany, Poveda Tags: Chemotherapy, Translational Oncology Sarcomas Source Type: research